AZTA vs SGRY

AZTA exhibits mixed financial health with a weak Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score to assess distress risk. While the company shows strong revenue visibility and improving earnings trends, elevated valuation metrics (P/E of 77.02 vs. sector average of 220.68) and negative profit margins (-9.39%) raise concerns. Recent insider selling and declining long-term price performance contrast with a positive short-term rebound and solid quarterly earnings surprises. The stock trades significantly above the Graham Number of $20.99, suggesting potential overvaluation relative to defensive criteria.

SGRY exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and deteriorating operational efficiency. While the stock trades at a low Price-to-Sales (0.55) and Price-to-Book (1.05) ratio, these valuation metrics are offset by negative profit margins and a disastrous earnings track record, with 0 beats in the last four quarters. Stagnant revenue growth (2.40%) and aggressive insider selling by the CEO and CFO further undermine the bullish analyst consensus. The combination of a 0/100 technical trend and consistent earnings misses suggests a value trap rather than a value opportunity.